RESEARCH
Home Introduction Divisions Organized Research Units Research Training Program Selected Scholarly Interests

Patricia W. Finn, MD. Department Chair

© Copyright 2014 The Board of Trustees of the University of Illinois

Richard M. Novak, M.D.


Academic Title: Professor of Clinical Medicine                                                                                        

Administrative Positions: Section Chief

Section: Infectious Diseases

Location: 808 S. Wood St., Rm. 888, CSN (MC 735), Chicago, IL 60612

Phone: (312)996-6732 (Office) Fax: (312)413-2944

E-mail: rmnovak@uic.edu


Education:

MD, Rush Medical College, Chicago, IL (1981)

Resident, University of Illinois at Chicago, Chicago, IL (1981-1984)

Fellow, University of Illinois at Chicago, Chicago, IL (1986-1989)


Faculty Positions:


Clinical Specialties


Research Interests


Selected Publications

  1. Bartholow BN, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, Creticos C, Orozco-Cronin P, Popovic V,  and Mastro TD for the VISION/VAX004 Study Team. HIV sexual risk behavior over 36-months of follow-up in the world’s first HIV vaccine efficacy trial. J. Acquir. Immune. Defic. Syndr. 39(1):90-101, 2005.
  2. Novak RM, Chen L, MacArthur RD, Baxter JD, Hullsiek KH, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M and the CPCRA 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment naïve participants: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40(3):468-474, 2005.
  3. Jendrysik MA, Ghassemi M, Graham PJ, Boksa LA, and Novak RM. Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intracellular adhesion molecule 3-grabbing nonintegrin. J. Infect. Dis. 192(4):630-639, 2005.
  4. Schneider JA, Alam SA, Ackers M, Parekh B, Chen HY, Graham P, Gurwith M, Mayer K, and Novak RM. Mucosal HIV binding antibody and neutralizing activity among high-risk HIV-uninfected female HIV vaccine trial participants. J. Infect. Dis. 196(11):1637-1644, 2007.
  5. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, and Landay A. Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women iwht a high risk of heterosecual acquisition of HIV infections. Clin. Vaccine Immunol.14(9):1102-1107, 2007.
  6. MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, and Dehlinger M for the CPCRA 058 Study Team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). A comparison of three highly active antiretroviral treatment strategies consisting of non-nuceloside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nulceoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study). Lancet 368(9553):2107-2109, 2006.
  7. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, Holmberg SD, and Brooks JT. Incidence of cancers among HIV-infected persons in the United States, 1992-2003. Ann. Internal Med. 148(10):728-736, 2008.
  8. Palella FJ Jr, Armon C, Buchacz K, Cole SR, Chmiel JS, Novak RM, Wood K, Moorman AC, Brooks JT, and the HIV Outpatient Study (HOPS) Investigators. The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: a cohort study. Ann. Internal Med. 51(2):73-84, 2009.
  9. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, and Sereti I for the INSIGHT Study Group. Higher levels of CRP, D-dimer, IL-6 and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J. Infect. Dis. 203(11):1637-1646, 2011.
  10. Palella FJ Jr, Baker RK, Buchacz K, Chmiel JS, Tedaldi EM, Novak RM, Durham MD, Brooks JT, and the HOPS Investigators. Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 25(15):1865-1876, 2011.
  11. Novak RM, Richardson JT, Buchacz K, Chmiel JS, Durham MD, Palella FJ Jr, Wendrow A, Wood K, Young B, Brooks­ JT, and the HOPS Investigators. Immune reconstitution inflammatory syndrome: incidence and inplications for mortality. AIDS 26(6):721-730, 2012.
  12. Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, Frank I, and the HVTN 906 study team. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906. J. Acquir. Immune Dific. Syndr. 63(2):239-244, 2013.
  13. Makinde HM, Zariffard R, Mirmonsef P, Novak RM, Jarrett O, Landay AL, and Spear GT. IL-22 levels are associated with trichomonas vaginalis infection in the lower genital tract. Am. J. Reprod. Immunol. Epub ahead of print Feb, 2013.
  14. Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa JP, Abdul-Jauwad H, Joseph P, Koenig E, Metzger D, Sobieszycz M, Tyndall M, and Zorilla C. Risk Behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition: the step study. AIDS. IN PRESS
  15. McElrath MJ, Smythe K, Randolph-Habecker J, Melton KR, Goodpaster TA, Hughes S, Mack M, Sato A, Diaz G, Steinbach G, Novak RM, Curlin M, Lord J, Maenza J, Duerr A, Frahm N, Hladik F,  and the NIAID HIV Vaccine Trails Network. Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility towards the anus. J. Acquir. Immune Dific. Syndr. Epub ahead of print Apr, 2013.